antivir
compound
evalu
efficaci
yellow
fever
viru
yfv
hamster
model
yfvinduc
liver
diseas
challeng
cell
cultur
infecti
dose
yfv
result
mortal
rate
femal
hamster
viru
detect
qrtpcr
liver
kidney
spleen
serum
peak
titer
day
postvir
challeng
dpi
serum
level
alkalin
phosphatas
alanin
aminotransferas
alt
bilirubin
blood
urea
nitrogen
potassium
creatinin
significantli
elev
serum
level
albumin
amylas
glucos
calcium
globulin
phosphoru
sodium
total
protein
significantli
reduc
pack
cell
volum
white
blood
cell
count
significantli
elev
cours
infect
intraperiton
treatment
hamster
interferon
ifn
mgkgd
viramidin
mgkgd
ribavirin
initi
h
prior
yfv
challeng
result
signific
improv
surviv
serum
alt
level
treatment
ifn
ribavirin
start
dpi
also
significantli
improv
surviv
serum
alt
level
hamster
challeng
yfv
preand
postviru
exposur
treatment
ifn
efficaci
improv
diseas
yfvinfect
hamster
specif
antivir
agent
treatment
yellow
fever
viru
yfv
despit
commerci
yfv
vaccin
still
approxim
death
worldwid
year
case
increas
last
year
tomori
viru
endem
africa
south
america
case
yfv
report
nonendem
area
travel
bae
et
al
mcfarland
et
al
viscerotrop
infect
also
occur
vaccin
also
risk
infect
vaccin
strain
anon
martin
et
al
vasconcelo
et
al
therefor
develop
therapi
treatment
yfv
diseas
import
endem
area
also
may
travel
endem
area
may
experi
diseas
vaccin
yfv
singlestrand
rna
viru
flavivirida
famili
relat
hepat
c
dengu
west
nile
virus
human
concern
mosquito
speci
aed
haemogogu
transmit
yfv
serv
reservoir
viru
human
monkey
primari
host
viral
infect
lourencodeoliveira
et
al
vasconcelo
et
al
diseas
may
limit
mild
febril
ill
may
sever
includ
jaundic
renal
failur
vascular
instabl
shock
monath
barrett
approxim
case
fatal
rate
sever
yfv
case
tomori
recent
nonhuman
primat
macaqu
squirrel
monkey
avail
anim
model
yfvinduc
liver
diseas
arroyo
et
al
guirakhoo
et
al
monath
et
al
develop
hamster
model
yfvinduc
liver
diseas
recent
describ
xiao
et
al
sbrana
et
al
avail
model
made
possibl
screen
potenti
antivir
agent
activ
viru
small
anim
model
purpos
studi
character
hamster
yfv
use
evalu
antivir
compound
efficaci
viru
jimenez
hamsteradapt
ha
yfv
kindli
provid
robert
tesh
univers
texa
medic
branch
galveston
tx
stock
viru
prepar
intraperiton
ip
inocul
adult
femal
hamster
liver
infect
hamster
remov
day
postviru
inject
dpi
homogen
x
volum
steril
pb
homogen
clarifi
allow
tissu
settl
minut
supernat
collect
frozen
aliquot
c
viru
titrat
hamster
dilut
use
subsequ
studi
dose
correspond
cell
cultur
infecti
dose
ccid
ml
determin
infecti
cell
cultur
assay
sixto
eightweekold
g
femal
syrian
golden
hamster
use
simonsen
laboratori
gilroy
ca
anim
challeng
intraperiton
ip
dilut
viru
stock
determin
accept
infecti
dose
hamster
randomli
assign
cage
given
food
water
ad
libitum
work
anim
perform
biosafeti
level
area
aaalacaccredit
laboratori
anim
research
center
larc
utah
state
univers
usu
interferon
ifn
infergen
consensustyp
interferon
provid
intermun
inc
brisban
ca
aqueou
solut
anim
treat
day
ifn
specif
activ
x
unitsmg
protein
present
studi
hamster
dose
ifn
convert
mukgday
ribavirin
provid
valeant
pharmaceut
costa
mesa
ca
use
mg
kgd
viramidin
ribamidin
also
provid
valeant
pharmaceut
use
mgkgd
compound
prepar
steril
physiolog
salin
prior
use
store
thereaft
primerpair
forward
agttgattccatcttgggcttc
revers
acctcttcctctccatcccatc
taqman
probe
n
n
specif
nucleotid
asibi
yfv
strain
use
qiagen
valencia
ca
onestep
brilliant
qrtpcr
master
mix
kit
stratagen
la
jolla
ca
use
rt
amplif
yfv
rna
primer
probe
rna
isol
tissu
use
trizol
invitrogen
carlsbad
ca
accord
manufactur
instruct
pellet
rna
reconstitut
depctreat
water
store
one
total
cellular
rna
total
extract
infect
control
tissu
use
sampl
run
dna
engin
opticon
mj
research
inc
waltham
revers
transcript
cellular
rna
perform
min
follow
pcr
consist
cycl
sec
result
given
term
rel
equival
reflect
amount
yfv
present
sampl
extrapol
standard
curv
obtain
amplif
dilut
total
rna
obtain
dpi
vero
cell
infect
yfv
volum
serum
obtain
necropsi
load
vetscan
comprehens
diagnost
profil
reagent
rotor
run
vetscan
chemistri
analyz
follow
manufactur
instruct
serum
level
alanin
aminotransferas
alt
albumin
alkalin
phosphatas
amylas
calcium
creatinin
globulin
glucos
phosphoru
potassium
sodium
total
bilirubin
total
protein
blood
urea
nitrogen
bun
measur
serum
alt
determin
use
alt
reagent
kit
teco
diagnost
anaheim
ca
volum
alt
substrat
place
well
plate
alt
substrat
serum
obtain
necropsi
store
use
ad
time
interv
follow
time
interv
incub
min
color
reagent
ad
well
anoth
incub
min
alt
color
develop
ad
mix
sampl
incub
addit
min
plate
read
spectramax
spectrophotomet
molecular
devic
sunnyval
ca
nm
normal
abnorm
control
sera
known
alt
concentr
use
posit
control
blood
sampl
approxim
ml
taken
necropsi
paramet
includ
pack
cell
volum
pcv
white
blood
cell
wbcc
count
record
day
viru
challeng
whole
blood
load
capillari
tube
plug
one
end
spun
minut
capillari
centrifug
pcv
measur
wbcc
whole
blood
ad
work
solut
crystal
violet
glacial
acet
acid
min
count
hemocytomet
stock
yfv
serial
dilut
undilut
dilut
minim
essenti
media
dilut
inject
ip
group
anim
mortal
record
dpi
daili
weight
chang
also
measur
individu
mark
anim
experi
repeat
anim
per
experiment
group
result
data
combin
result
first
titrat
experi
hamster
challeng
ip
dilut
stock
yfv
day
day
viru
challeng
liver
kidney
spleen
serum
sampl
obtain
anim
tissu
analyz
variou
paramet
includ
tissu
viru
titer
serum
ion
protein
measur
vetscan
instrument
pcv
wbcc
hamster
challeng
ip
dilut
stock
yfv
treat
ip
variou
dilut
ifn
mgkgd
ribavirin
start
h
prior
viru
challeng
continu
dpi
ifn
treatment
given
daili
ribavirin
treatment
administ
twice
daili
hour
apart
serum
sampl
analyz
alt
level
dpi
time
alt
reach
peak
valu
weight
chang
measur
dpi
timepoint
allow
maximum
statist
differ
weight
chang
observ
yfvinfect
hamster
prior
highest
death
rate
infect
anim
second
studi
viramidin
mgkgd
administ
ip
twicedaili
h
prior
viru
challeng
dpi
serum
sampl
taken
alt
measur
mortal
observ
dpi
weight
chang
also
measur
dpi
third
experi
treatment
ifn
ribavirin
initi
dpi
anim
treat
follow
dose
schedul
dpi
see
treatment
initi
later
infect
would
effect
increas
surviv
reduc
weight
loss
reduc
serum
alt
level
mortal
observ
dpi
mean
day
death
calcul
ttest
use
determin
statist
differ
vetscan
assay
result
serum
alt
level
test
group
placebotr
control
wilcoxon
logrank
test
use
analysi
surviv
data
group
hamster
inocul
serial
dilut
viru
stock
mortal
occur
vari
degre
viru
challeng
group
mortal
mean
day
death
mdd
correl
viru
challeng
tabl
signific
weight
loss
also
observ
anim
infect
undilut
stock
yfv
weight
chang
correl
dilut
yfv
stock
group
challeng
weight
gain
group
challeng
dilut
stock
viru
weight
loss
observ
viru
dilut
group
greatest
weight
loss
undilut
viru
stock
tabl
highli
signific
differ
surviv
signific
differ
weight
gain
dpi
observ
group
hamster
challeng
dilut
ccid
ml
compar
shaminfect
anim
signific
differ
paramet
dilut
viru
challeng
use
subsequ
experi
group
hamster
challeng
dilut
viru
stock
tissu
sampl
obtain
hamster
remain
hamster
challeng
yfv
use
sampl
collect
anim
die
prior
dpi
tissu
sampl
includ
liver
kidney
spleen
serum
obtain
day
viru
challeng
assay
biochem
viral
paramet
tissu
yfv
titer
detect
qrtpcr
liver
spleen
kidney
serum
reach
peak
level
approxim
dpi
fig
respect
highest
titer
log
viru
detect
liver
unexpect
serum
paramet
measur
use
vetscan
comprehens
diagnost
profil
cartridg
serum
level
alkalin
phosphatas
alt
bilirubin
bun
potassium
creatinin
significantli
elev
point
cours
infect
serum
level
albumin
amylas
glucos
calcium
globulin
phosphoru
sodium
total
protein
significantli
reduc
tabl
approxim
half
anim
observ
discolor
icter
liver
notic
dpi
correl
icter
serum
data
shown
wbcc
log
significantli
elev
dpi
compar
shaminfect
control
respect
red
blood
cell
pcv
also
significantli
increas
dpi
compar
shaminfect
control
first
treatment
studi
anim
challeng
dilut
yfv
stock
treat
ifn
ribavirin
h
dpi
complet
surviv
anim
treat
ifn
highli
signific
compar
placebo
treatment
tabl
treatment
hamster
mgkgd
ifn
also
result
signific
improv
surviv
although
mortal
observ
ribavirin
treatment
mgkgd
also
result
signific
improv
surviv
although
mgkgd
improv
diseas
paramet
weight
loss
also
markedli
reduc
ifn
treatment
group
well
mgkgd
ribavirin
tabl
serum
alt
level
significantli
lower
ifn
mgkgd
ribavirintr
group
compar
placebo
serum
sampl
obtain
ifn
anim
clear
sera
mgkgd
ribavirintr
anim
ifn
mgkgd
ribavirin
placebotr
anim
icter
correl
high
serum
alt
valu
addit
studi
conduct
use
viramidin
deriv
ribavirin
treatment
yfv
viramidin
also
significantli
improv
surviv
reduc
weight
loss
anim
challeng
yfv
tabl
treatment
viramidin
also
significantli
reduc
serum
alt
level
normal
pretreat
level
tabl
also
differ
serum
mice
obtain
viramidinetr
anim
clear
serum
sampl
obtain
placebotr
anim
icter
yellow
color
icter
serum
also
correl
death
high
alt
valu
tabl
third
studi
treatment
initi
dpi
ifn
ribavirin
later
treatment
also
effect
significantli
improv
surviv
highli
signific
decreas
serum
alt
level
anim
treat
ribavirin
slightli
signific
serum
alt
decreas
hamster
treat
ifn
tabl
also
signific
reduct
weight
loss
ifn
anim
anim
treat
ribavirin
tabl
addit
alter
variou
paramet
previous
describ
hamster
model
sbrana
et
al
also
identifi
alter
paramet
tissu
titer
measur
qrtpcr
peak
dpi
reduc
dpi
liver
kidney
spleen
serum
high
titer
found
liver
spleen
yfvinfect
patient
correl
rapid
diseas
progress
bae
et
al
de
brito
et
al
weight
chang
also
appear
good
indic
drug
efficaci
treatment
treat
anim
gener
lose
less
weight
gain
weight
compar
anim
treat
placebo
serum
paramet
ie
alkalin
phosphatas
calcium
creatinin
globulin
glucos
phosphoru
sodium
total
protein
measur
result
gave
overal
pictur
sever
liver
kidney
diseas
serum
paramet
significantli
reduc
could
potenti
use
determin
efficaci
antivir
drug
serum
alt
use
avail
reagent
cost
import
liver
diseas
measur
titrat
viru
stock
hamster
reveal
hamster
suscept
dilut
viru
stock
correl
ccid
interest
lower
mortal
observ
higher
viru
challeng
dose
infect
seem
dose
depend
like
due
mani
differ
factor
process
infect
anim
model
defect
interf
particl
initi
replic
lymph
node
immun
recognit
other
barrett
et
al
vlaycheva
et
al
melhop
diamond
high
variabl
observ
studi
limit
model
mortal
rate
observ
inoculum
serum
alt
highli
variabl
determin
number
anim
need
gener
statist
signific
light
variabl
observ
statist
power
analysi
perform
data
character
experi
indic
experi
use
paramet
evalu
antivir
compound
would
need
includ
least
anim
per
group
juland
unpublish
data
paramet
test
studi
similar
mani
respect
publish
result
sbrana
et
al
mortal
weekold
hamster
rang
placebotr
control
anim
allow
signific
differ
antivir
placebo
treatment
observ
serum
alt
bilirubin
bun
potassium
albumin
amylas
similar
peak
publish
previous
viremia
follow
similar
time
cours
previous
report
data
peak
titer
dpi
statist
signific
elev
wbc
count
observ
dpi
pcv
dpi
correl
elev
wbc
count
pcv
previous
report
tesh
associ
demonstr
treatment
ifn
reduc
mortal
weight
loss
serum
alt
level
even
treatment
initi
day
viru
challeng
treatment
ifn
appear
dose
respons
higher
surviv
greater
improv
diseas
paramet
highest
dose
diminish
effect
lower
dose
cytokin
result
surpris
ifn
shown
efficaci
differ
flavivirus
well
group
virus
gowen
et
al
loutfi
et
al
morrey
et
al
morrey
et
al
sjogren
et
al
ifn
treatment
effect
administ
dpi
studi
aim
determin
late
treatment
may
initi
compound
reduc
mortal
viral
paramet
rel
biolog
potenc
ifn
hamster
compar
human
approxim
less
hu
et
al
therefor
estim
biolog
potenc
ifn
unit
given
hamster
studi
ukgday
fda
approv
human
dose
ifn
treatment
chronic
hepat
c
human
mu
averag
chronic
hepat
c
patient
weigh
approxim
kg
result
approv
dose
ifn
approxim
ukg
thu
hamster
studi
treat
therapeut
relev
dose
ifn
viramidin
prodrug
ribavirin
convert
ribavirin
liver
cell
uptak
reduc
toxic
better
livertarget
properti
compar
ribavirin
treatment
lin
et
al
sidwel
et
al
viramidin
treatment
result
highli
signific
reduct
serum
alt
p
compar
placebo
previou
studi
demonstr
util
ribavirin
treatment
improv
surviv
reduc
serum
alt
sbrana
et
al
ribavirin
improv
weight
chang
either
treatment
regimen
may
due
slight
toxic
effect
compound
serum
alt
level
seem
good
indic
treatment
success
appear
correl
alt
level
mortal
anim
alt
level
time
greater
normal
gener
die
icter
serum
correl
high
alt
level
well
fatti
liver
could
serv
indic
anim
would
potenti
die
infect
higher
mortal
observ
hepat
c
virusinfect
patient
chronic
elev
alt
level
compar
patient
elev
bestard
et
al
similar
reduct
alt
mortal
also
seen
mice
infect
murin
cytomegaloviru
treat
hpmpc
gancyclovir
bolger
et
al
serum
alt
level
may
serv
marker
death
yfvinfect
hamster
measur
quantifi
paramet
serum
alt
tissu
titer
mortal
weight
chang
hamster
model
yfv
infect
use
experi
evalu
antivir
compound
efficaci
yfv
need
antivir
agent
effect
treatment
yfv
infect
model
may
instrument
determin
possibl
treatment
may
reduc
morbid
mortal
caus
yfv
timecours
viru
titer
variou
organ
taken
hamster
challeng
jimenez
yellow
fever
viru
measur
qrtpcr
effect
ip
treatment
interferon
ribavirin
viramidin
hamster
infect
hamsteradapt
yellow
fever
viru
